2004
DOI: 10.1016/j.ahj.2004.03.050
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of hyperlipidemia in cardiac transplant recipients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
56
0

Year Published

2009
2009
2023
2023

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 58 publications
(56 citation statements)
references
References 64 publications
0
56
0
Order By: Relevance
“…The hypothesis of these nephrotoxicity as indicated in the present study, has been proposed that CsA alters the balance between vasodilators and vasoconstrictors in kidney with predominance of vasoconstrictors and vascular smooth muscle cells proliferation in the intima and accumulation of cholesterol esters in macrophages that can be transformed in foam cells in vessel wall with narrowing of vessel lumen (Beckman et al, 2002). Several studies indicate that vascular dysfunction induced by CsA results from an increase in vasoconstrictor factors such as endothelin, thromboxane, and angiotensin II and at the same time a reduction of vasodilator factors such as prostacyclin and nitric oxide (NO) (Parra et al, 1998;Markell et al, 1994;Bilchick et al, 2004;Baid et al, 2001;Halliwell and Gutteridge, 1999). Therefore, an imbalance in the release of vasoactive substances is related to renal vasoconstriction.…”
Section: Resultsmentioning
confidence: 99%
“…The hypothesis of these nephrotoxicity as indicated in the present study, has been proposed that CsA alters the balance between vasodilators and vasoconstrictors in kidney with predominance of vasoconstrictors and vascular smooth muscle cells proliferation in the intima and accumulation of cholesterol esters in macrophages that can be transformed in foam cells in vessel wall with narrowing of vessel lumen (Beckman et al, 2002). Several studies indicate that vascular dysfunction induced by CsA results from an increase in vasoconstrictor factors such as endothelin, thromboxane, and angiotensin II and at the same time a reduction of vasodilator factors such as prostacyclin and nitric oxide (NO) (Parra et al, 1998;Markell et al, 1994;Bilchick et al, 2004;Baid et al, 2001;Halliwell and Gutteridge, 1999). Therefore, an imbalance in the release of vasoactive substances is related to renal vasoconstriction.…”
Section: Resultsmentioning
confidence: 99%
“…Other agents that may be safe to use for hyperlipidemia in cases requiring concomitant cyclosporine treatment are fibrate and niacin [53]. In addition, if a patient on cyclosporine is prescribed simvastatin, its dosage should be reduced [57].…”
Section: Discussionmentioning
confidence: 99%
“…Characterization of the NPC1L1 pathway revealed that ezetimibe specically binds to NPC1L1 and inhibits its sterol transport function, and it is now widely used in combination therapy with statins for management of hypercholesterolemia in the general population [20]. In liver, cardiac and kidney transplant patients, hypercholesterolemia could be e ectively treated with ezetimibe with few side e ects [21][22][23]. e present study suggests that the signi cantly increased expression of NPC1L1 might promote intestinal cholesterol absorption, which might contribute to hypercholesterolemia involved in the development of CR; however, other important aspects of cholesterol metabolism were not studied simultaneously.…”
Section: Discussionmentioning
confidence: 99%